UCB (OTCMKTS:UCBJF) Sees Strong Trading Volume – Should You Buy?

UCB SA (OTCMKTS:UCBJF) shares saw an uptick in trading volume on Friday . 3,554 shares were traded during trading, an increase of 380% from the previous session’s volume of 741 shares.The stock last traded at $321.05 and had previously closed at $310.00.

Analysts Set New Price Targets

Several analysts have commented on the stock. Wolfe Research assumed coverage on shares of UCB in a report on Monday, February 23rd. They set an “outperform” rating on the stock. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a report on Monday, February 16th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The business has a 50-day simple moving average of $295.42 and a two-hundred day simple moving average of $299.03.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.